{"id":"NCT05412004","sponsor":"Eli Lilly and Company","briefTitle":"Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea","officialTitle":"A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-06-21","primaryCompletion":"2024-03-12","completion":"2024-03-29","firstPosted":"2022-06-09","resultsPosted":"2025-04-30","lastUpdate":"2025-04-30"},"enrollment":469,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Obstructive Sleep Apnea","Obesity"],"interventions":[{"type":"DRUG","name":"Tirzepatide","otherNames":["LY3298176"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tirzepatide MTD_GPI1","type":"EXPERIMENTAL"},{"label":"Placebo_GPI1","type":"PLACEBO_COMPARATOR"},{"label":"Tirzepatide MTD_GPI2","type":"EXPERIMENTAL"},{"label":"Placebo_GPI2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP) therapy in GPI1 and those who are and plan to stay on PAP therapy in GPI2.","primaryOutcome":{"measure":"Change From Baseline in Apnea-Hypopnea Index (AHI)","timeFrame":"Baseline, Week 52","effectByArm":[{"arm":"Tirzepatide MTD_GPI1","deltaMin":-25.25,"sd":2.06},{"arm":"Placebo_GPI1","deltaMin":-5.25,"sd":2.11},{"arm":"Tirzepatide MTD_GPI2","deltaMin":-29.27,"sd":1.99},{"arm":"Placebo_GPI2","deltaMin":-5.51,"sd":2.21}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG002 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":14},"locations":{"siteCount":58,"countries":["United States","Australia","Brazil","China","Czechia","Germany","Japan","Mexico","Puerto Rico","Taiwan"]},"refs":{"pmids":["40774158","38912654","38547961"],"seeAlso":["https://clinicaltrials.gov/study/NCT05412004?tab=results"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":114},"commonTop":["Diarrhoea","Nausea","Constipation","Nasopharyngitis","Vomiting"]}}